Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus Chemotherapy in Advanced Cancer
NCT02423954Phase 2Terminated
- Sponsor
- Western Regional Medical Center
- Start
- Apr 2015
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in pancreatic cancer (PC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC) and 3 more (3 arms), sponsored by Western Regional Medical Center. Primary endpoint: Recommended Phase 2 Dose at 4 weeks. Started Apr 2015; status: terminated.
02
Drugs
03
Conditions
pancreatic cancer (PC)renal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02423954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02423954.